Traws Pharma, Inc. (TRAW)
$0.41-2.38%Close
SELLCRISIS · day 7
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4M
- Beta
- 1.53
- P/E (TTM)
- -0.82
- Short % float
- 11.59%
- Days to cover
- 1.0
- SI change
- +12.8%
- 1W
- -21.15%
- 1M
- -21.15%
- vs SPY 1W
- -21.02%
- vs SPY 1M
- -23.66%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 14
- GROWTH
- 35
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC212.1%
REV YoY-
ROE353.4%
EPS YoY-
ROA-128.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.82
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-0.82
P/FCF-
EV/EBITDA-0.22
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.43
ND/EBITDA-
BETA1.53
Company news
FAQ
- What is LOPJLB’s current signal on TRAW?
- LOPJLB’s latest quantitative signal on Traws Pharma, Inc. (TRAW) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TRAW in?
- Traws Pharma, Inc. (TRAW) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Traws Pharma, Inc. (TRAW) do?
- Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (trav…